|
Giredestrant Clinical Trials
7 actively recruiting trials across 4 locations
▼ -1 trial since August 2026
Also known as: GDC-9545, RG6171, RO7197597
Pipeline
Phase 2: 2Phase 3: 1Phase 1/2: 4
Top Sponsors
- Hoffmann-La Roche3
- Genentech, Inc.2
- MedSIR1
- Alliance Foundation Trials, LLC.1
Indications
- Cancer7
- Breast Cancer6
- Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer1
- Metastatic Breast Cancer1
- Early Breast Cancer1
Duarte, California3 trials
Phase 1/2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
City of Hope - Duarte
Phase 1/2
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
City of Hope Comprehensive Cancer Center
Phase 1/2
Other1 trial
Tucson, Arizona1 trial
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
University of Arizona Cancer Center
Phase 1/2
Fountain Valley, California1 trial
Los Angeles, California1 trial
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Los Angeles Cancer Network
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.